{"id":4636,"date":"2026-02-25T17:14:59","date_gmt":"2026-02-25T17:14:59","guid":{"rendered":"https:\/\/vantagebiotrials.com\/?p=4636"},"modified":"2026-03-30T18:24:38","modified_gmt":"2026-03-30T18:24:38","slug":"snmmi-annual-meeting-may-30-june-2-2026","status":"publish","type":"post","link":"https:\/\/vantagebiotrials.com\/fr\/snmmi-annual-meeting-may-30-june-2-2026\/","title":{"rendered":"SNMMI Annual Meeting | May 30 \u2013 June 2, 2026"},"content":{"rendered":"<h2 data-section-id=\"k93wih\" data-start=\"581\" data-end=\"619\"><span role=\"text\"><strong data-start=\"584\" data-end=\"619\">Vantage BioTrials at SNMMI 2026<\/strong><\/span><\/h2>\n<p data-start=\"621\" data-end=\"785\"><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Vantage BioTrials<\/span><\/span> will attend the <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Society of Nuclear Medicine and Molecular Imaging<\/span><\/span> Annual Meeting (SNMMI 2026) from May 30 to June 2, 2026.<\/p>\n<p data-start=\"787\" data-end=\"990\">This global event brings together leaders in nuclear medicine, molecular imaging, and radiopharmaceutical development. It creates a space to share scientific advances and discuss real-world applications.<\/p>\n<p data-start=\"992\" data-end=\"1163\">As innovation accelerates, clinical trial execution becomes more specialized. As a result, sponsors must rely on strong operational oversight and clear coordination.<\/p>\n<hr data-start=\"1165\" data-end=\"1168\" \/>\n<h2 data-section-id=\"1r9k1kz\" data-start=\"1170\" data-end=\"1208\"><span role=\"text\"><strong data-start=\"1173\" data-end=\"1208\">Meet the Vantage BioTrials Team<\/strong><\/span><\/h2>\n<p data-start=\"1210\" data-end=\"1264\">Representing Vantage BioTrials at the meeting will be:<\/p>\n<ul data-start=\"1266\" data-end=\"1407\">\n<li data-section-id=\"1rgqgpr\" data-start=\"1266\" data-end=\"1322\"><strong data-start=\"1268\" data-end=\"1309\"><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Vatche Bartekian<\/span><\/span><\/strong>, President<\/li>\n<li data-section-id=\"yiu7zu\" data-start=\"1323\" data-end=\"1407\"><strong data-start=\"1325\" data-end=\"1366\"><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Viken Bartekian<\/span><\/span><\/strong>, Vice President, Corporate Development<\/li>\n<\/ul>\n<p data-start=\"1409\" data-end=\"1545\">They look forward to connecting with sponsors, investigators, and partners working in radiopharmaceutical and imaging-based development.<\/p>\n<hr data-start=\"1547\" data-end=\"1550\" \/>\n<h2 data-section-id=\"fnr1jj\" data-start=\"1552\" data-end=\"1603\"><span role=\"text\"><strong data-start=\"1555\" data-end=\"1603\">Radiopharmaceutical Clinical Trial Expertise<\/strong><\/span><\/h2>\n<p data-start=\"1605\" data-end=\"1780\">Radiopharmaceutical trials require a specialized operational approach. These studies involve complex logistics, strict regulatory expectations, and coordinated site execution.<\/p>\n<p data-start=\"1782\" data-end=\"1838\">At Vantage BioTrials, we support these programs through:<\/p>\n<ul data-start=\"1840\" data-end=\"2125\">\n<li data-section-id=\"1rhac4c\" data-start=\"1840\" data-end=\"1902\">Coordination with nuclear medicine teams and imaging sites<\/li>\n<li data-section-id=\"gnnrn3\" data-start=\"1903\" data-end=\"1962\">Oversight of radiopharmaceutical handling and logistics<\/li>\n<li data-section-id=\"bs4v7y\" data-start=\"1963\" data-end=\"2019\">Support for imaging endpoints and centralized review<\/li>\n<li data-section-id=\"1wmy84p\" data-start=\"2020\" data-end=\"2075\">Risk-based monitoring tailored to complex protocols<\/li>\n<li data-section-id=\"1dc5hk1\" data-start=\"2076\" data-end=\"2125\">Collaboration with specialized clinical sites<\/li>\n<\/ul>\n<p data-start=\"2127\" data-end=\"2365\">In addition, our approach is grounded in Quality by Design (QbD). It also integrates proactive risk mitigation from the earliest stages. Therefore, teams can identify risks early and manage them throughout the trial lifecycle.<\/p>\n<p data-start=\"2367\" data-end=\"2462\">\ud83d\udc49 Learn more about our <a title=\"Therapeutic Expertise\" href=\"https:\/\/vantagebiotrials.com\/therapeutic-area\/\" target=\"_blank\" rel=\"noopener\">therapeutic expertise<\/a> .<\/p>\n<hr data-start=\"2464\" data-end=\"2467\" \/>\n<h2 data-section-id=\"14kzqny\" data-start=\"2469\" data-end=\"2506\"><span role=\"text\"><strong data-start=\"2472\" data-end=\"2506\">What We\u2019re Focused On at SNMMI<\/strong><\/span><\/h2>\n<p data-start=\"2508\" data-end=\"2655\">Today, radiopharmaceutical development continues to evolve. Consequently, clinical programs require greater coordination and operational precision.<\/p>\n<p data-start=\"2657\" data-end=\"2697\">At SNMMI, we look forward to discussing:<\/p>\n<ul data-start=\"2699\" data-end=\"2910\">\n<li data-section-id=\"108f85k\" data-start=\"2699\" data-end=\"2752\">Managing complexity in radiopharmaceutical trials<\/li>\n<li data-section-id=\"14hbja2\" data-start=\"2753\" data-end=\"2811\">Coordinating imaging infrastructure and site readiness<\/li>\n<li data-section-id=\"1vfyv1o\" data-start=\"2812\" data-end=\"2864\">Maintaining data quality and protocol compliance<\/li>\n<li data-section-id=\"1wzs9ld\" data-start=\"2865\" data-end=\"2910\">Applying structured, risk-based oversight<\/li>\n<\/ul>\n<p data-start=\"2912\" data-end=\"3059\">These priorities are directly linked to successful execution. As a result, alignment between sponsors and CRO partners remains essential.<\/p>\n<hr data-start=\"3061\" data-end=\"3064\" \/>\n<h2 data-section-id=\"dly7r0\" data-start=\"3066\" data-end=\"3084\"><span role=\"text\"><strong data-start=\"3069\" data-end=\"3084\">About SNMMI<\/strong><\/span><\/h2>\n<p data-start=\"3086\" data-end=\"3220\">The <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Society of Nuclear Medicine and Molecular Imaging<\/span><\/span> Annual Meeting is a leading global conference in nuclear medicine and molecular imaging.<\/p>\n<p data-start=\"3222\" data-end=\"3364\">It brings together clinicians, researchers, and industry leaders. Together, they advance innovation across diagnostics and targeted therapies.<\/p>\n<p data-start=\"3366\" data-end=\"3423\">\ud83d\udc49 Learn more about the meeting: <a class=\"decorated-link\" title=\"SNMMI\" href=\"https:\/\/www.snmmi.org\/\" target=\"_blank\" rel=\"noopener\" data-start=\"3401\" data-end=\"3423\">https:\/\/www.snmmi.org\/<\/a><\/p>\n<hr data-start=\"3425\" data-end=\"3428\" \/>\n<h2 data-section-id=\"14gtz2a\" data-start=\"3430\" data-end=\"3467\"><span role=\"text\"><strong data-start=\"3433\" data-end=\"3467\">Connect with Vantage BioTrials<\/strong><\/span><\/h2>\n<p data-start=\"3469\" data-end=\"3544\">If you will be attending SNMMI 2026, we welcome the opportunity to connect.<\/p>\n<p data-start=\"3546\" data-end=\"3737\">We would be pleased to discuss how disciplined clinical trial management, proactive risk mitigation, and collaborative execution can support your radiopharmaceutical development programs.<\/p>","protected":false},"excerpt":{"rendered":"<p>Vantage BioTrials at SNMMI 2026 Vantage BioTrials will attend the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2026) from May 30 to June 2, 2026. This global event brings together leaders in nuclear medicine, molecular imaging, and radiopharmaceutical development. It creates a space to share scientific advances and discuss real-world applications. As innovation accelerates, clinical trial execution becomes more specialized. As a result, sponsors must rely on strong operational oversight and clear coordination. Meet the Vantage BioTrials Team Representing Vantage BioTrials at the meeting will be: Vatche Bartekian, President Viken Bartekian, Vice President, Corporate Development They look forward to connecting with sponsors, investigators, and partners working in radiopharmaceutical and imaging-based development. Radiopharmaceutical Clinical Trial Expertise Radiopharmaceutical trials require a specialized operational approach. These studies involve complex logistics, strict regulatory expectations, and coordinated site execution. At Vantage BioTrials, we support these programs through: Coordination with nuclear medicine teams and imaging sites Oversight of radiopharmaceutical handling and logistics Support for imaging endpoints and centralized review Risk-based monitoring tailored to complex protocols Collaboration with specialized clinical sites In addition, our approach is grounded in Quality by Design (QbD). It also integrates proactive risk mitigation from the earliest stages. Therefore, teams can identify risks early and manage them throughout the trial lifecycle. \ud83d\udc49 Learn more about our therapeutic expertise . What We\u2019re Focused On at SNMMI Today, radiopharmaceutical development continues to evolve. Consequently, clinical programs require greater coordination and operational precision. At SNMMI, we look forward to discussing: Managing complexity in radiopharmaceutical trials Coordinating imaging infrastructure and site readiness Maintaining data quality and protocol compliance Applying structured, risk-based oversight These priorities are directly linked to successful execution. As a result, alignment between sponsors and CRO partners remains essential. About SNMMI The Society of Nuclear Medicine and Molecular Imaging Annual Meeting is a leading global conference in nuclear medicine and molecular imaging. It brings together clinicians, researchers, and industry leaders. Together, they advance innovation across diagnostics and targeted therapies. \ud83d\udc49 Learn more about the meeting: https:\/\/www.snmmi.org\/ Connect with Vantage BioTrials If you will be attending SNMMI 2026, we welcome the opportunity to connect. We would be pleased to discuss how disciplined clinical trial management, proactive risk mitigation, and collaborative execution can support your radiopharmaceutical development programs.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[19],"tags":[],"class_list":["post-4636","post","type-post","status-publish","format-standard","hentry","category-events","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=4636"}],"version-history":[{"count":3,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4636\/revisions"}],"predecessor-version":[{"id":4875,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4636\/revisions\/4875"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=4636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=4636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=4636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}